Table 2.

Clinical and pathological characteristics

Variables	Total patients	GPER1 higher	GPER1 lower	P-value
Total	167	84	83
Age (years)
>50	106 (63.5%)	56	50
≤50	61 (36.5%)	28	33	0.389
T stage
T1	42 (25.1%)	20	22
T2 and T3	125 (74.9%)	64	61	0.688
N stage
Positive	76 (45.5%)	39	37
Negative	67 (40.1%)	28	39	0.255
Unknown	24 (14.4%)	17	7
ER
Positive	126 (75.4%)	69	57
Negative	41 (24.6%)	15	26	0.043
HER2
Positive	56 (33.5%)	23	33
Negative	111 (66.5%)	61	50	0.090
TAM
Yes	45 (26.9%)	25	20
No	122 (73.1%)	59	63	0.409
Other endoa
Yes	93 (55.7%)	51	42
No	74 (44.3%)	33	41	0.188
Chemotherapy
Yes	148 (88.6%)	75	73
No	19 (11.4%)	9	10	0.786

Note:

^aOther endo: other endocrine therapy except for TAM.

Abbreviations: GPER1, G protein-coupled estrogen receptor 1; TAM, tamoxifen treatment.